Human Papillomavirus Vaccination: Making Sense of the Public Controversy

Chapter
First Online:

Abstract

A large body of evidence supports the prevailing scientific opinion that human papillomavirus (HPV) vaccines are efficacious, safe, and cost-effective. Since first licensure in 2006, however, HPV vaccines have sparked unjustified controversy over their effectiveness, safety and risks, utility, and ethical implementation. We discuss various public criticisms relating to HPV vaccination and the weight of the evidence and counterarguments concerning each. These criticisms can be classified as follows: (1) effectiveness (lack of demonstrated efficacy against cervical cancer, lack of vaccine clinical trial data in targeted age groups, and limited HPV type protection of first-generation vaccines), (2) safety and risk (concerns regarding potential serious adverse health events linked with vaccination, effect of vaccines on prevalent infections, and potential sexual disinhibition caused by vaccination), (3) utility (disputing the added value of vaccination on the grounds of financial conflicts of interests, the low risk of cervical cancer consequent to screening, and the cost-effectiveness of vaccination), and (4) ethics (concerns regarding informed consent and self-determination in vaccination programs, the social justice of vaccine distribution, and gender equity). Most HPV vaccine controversies stem from misinformation and distrust of institutions. Public health institutions must deploy effective communication strategies to address ill-founded criticisms, enable informed consent, and foster public confidence in HPV vaccines.

Keywords

Human papillomavirus HPV Vaccine Vaccination Controversy Safety Cost-effectiveness Utility Informed consent Equity 

Abbreviations

CIN

Cervical intraepithelial neoplasia

CRPS

Complex regional pain syndrome

HPV

Human papillomavirus

MSM

Men who have sex with men

NCI

National Cancer Institute

POTS

Postural orthostatic tachycardia syndrome

RCT

Randomized clinical trial

STI

Sexually transmitted infection

US

United States

VAERS

Vaccine Adverse Event Reporting System

WHO

World Health Organization

This is a preview of subscription content, log in to check access.

References

  1. van’t Klooster TM, Kemmeren JM, van der Maas NAT, de Melker HE. Reported adverse events in girls aged 13–16 years after vaccination with the human papillomavirus (HPV)-16/18 vaccine in the Netherlands. Vaccine. 2011;29:4601–7. doi: 10.1016/j.vaccine.2011.04.050.PubMedCrossRefGoogle Scholar
  2. Abdelmutti N, Hoffman-Goetz L. Risk messages about HPV, cervical cancer, and the HPV vaccine Gardasil: a content analysis of Canadian and U.S. National Newspaper Articles. Women Health. 2009;49:422–40. doi: 10.1080/03630240903238776.PubMedCrossRefGoogle Scholar
  3. Agence Nationale de Sécurité du Médicament et des Produits de Santé. Vaccins anti-HPV et risque de maladies autoimmunes: étude pharmacoépidémiologique. 2015.Google Scholar
  4. Ali H, Donovan B, Wand H, Read TR, Regan DG, Grulich AE, Fairley CK, Guy RJ. Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data. BMJ. 2013;346:f2032. doi: 10.1136/bmj.f2032.PubMedCrossRefGoogle Scholar
  5. Andrae B, Kemetli L, Sparen P, Silfverdal L, Strander B, Ryd W, Dillner J, Tornberg S. Screening-preventable cervical cancer risks: evidence from a nationwide audit in Sweden. J Natl Cancer Inst. 2008;100:622–9. doi: 10.1093/jnci/djn099.PubMedCrossRefGoogle Scholar
  6. Arbyn M, Bergeron C, Klinkhamer P, Martin-Hirsch P, Siebers AG, Bulten J. Liquid compared with conventional cervical cytology: a systematic review and meta-analysis. Obstet Gynecol. 2008;111:167–77. doi: 10.1097/01.AOG.0000296488.85807.b3.PubMedCrossRefGoogle Scholar
  7. Arbyn M, Kyrgiou M, Simoens C, Raifu AO, Koliopoulos G, Martin-Hirsch P, Prendiville W, Paraskevaidis E. Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: meta-analysis. BMJ. 2008;337:a1284. doi: 10.1136/bmj.a1284.PubMedPubMedCentralCrossRefGoogle Scholar
  8. Arnheim-Dahlström L, Pasternak B, Svanström H, Sparén P, Hviid A. Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study. BMJ : British Medical Journal. 2013;347:f5906. doi: 10.1136/bmj.f5906.PubMedPubMedCentralCrossRefGoogle Scholar
  9. Backes DM, Kurman RJ, Pimenta JM, Smith JS. Systematic review of human papillomavirus prevalence in invasive penile cancer. Cancer Causes Control. 2009;20:449–57. doi: 10.1007/s10552-008-9276-9.PubMedCrossRefGoogle Scholar
  10. Baden LR, Curfman GD, Morrissey S, Drazen JM. Human papillomavirus vaccine — opportunity and challenge. N Engl J Med. 2007;356:1990–1. doi: 10.1056/NEJMe078088.PubMedCrossRefGoogle Scholar
  11. Baldur-Felskov B, Dehlendorff C, Munk C, Kjaer SK. Early impact of human papillomavirus vaccination on cervical neoplasia—Nationwide follow-up of young Danish women. J Natl Cancer Inst. 2014;106:djt460. doi: 10.1093/jnci/djt460.PubMedCrossRefGoogle Scholar
  12. Baril L, Rosillon D, Willame C, Angelo MG, Zima J, van den Bosch JH, Van Staa T, Boggon R, Bunge EM, Hernandez-Diaz S, Chambers CD. Risk of spontaneous abortion and other pregnancy outcomes in 15–25 year old women exposed to human papillomavirus-16/18 AS04-adjuvanted vaccine in the United Kingdom. Vaccine. 2015;33:6884–91. doi: 10.1016/j.vaccine.2015.07.024.PubMedCrossRefGoogle Scholar
  13. Beachler DC, Kreimer AR, Schiffman M, Herrero R, Wacholder S, Rodriguez AC, Lowy DR, Porras C, Schiller JT, Quint W, Jimenez S, Safaeian M, Struijk L, Schussler J, Hildesheim A, Gonzalez P, Group ftCRHVT. Multisite HPV16/18 vaccine efficacy against cervical, anal, and oral HPV infection. J Natl Cancer Inst. 2016;108:djv302. doi: 10.1093/jnci/djv302.PubMedCrossRefGoogle Scholar
  14. Bednarczyk RA, Davis R, Ault K, Orenstein W, Omer SB. Sexual activity–related outcomes after human papillomavirus vaccination of 11- to 12-year-olds. Pediatrics. 2012;130:798–805.PubMedCrossRefGoogle Scholar
  15. Benard VB, Johnson CJ, Thompson TD, Roland KB, Lai SM, Cokkinides V, Tangka F, Hawkins NA, Lawson H, Weir HK. Examining the association between socioeconomic status and potential human papillomavirus-associated cancers. Cancer. 2008;113:2910–8. doi: 10.1002/cncr.23742.PubMedCrossRefGoogle Scholar
  16. Bingham A, Drake J, LaMontagne D. Sociocultural issues in the introduction of human papillomavirus vaccine in low-resource settings. Arch Pediatr Adolesc Med. 2009;163:455–61. doi: 10.1001/archpediatrics.2009.50.PubMedCrossRefGoogle Scholar
  17. Blakely T, Kvizhinadze G, Karvonen T, Pearson AL, Smith M, Wilson N. Cost-effectiveness and equity impacts of three HPV vaccination programmes for school-aged girls in New Zealand. Vaccine. 2014;32:2645–56. doi: 10.1016/j.vaccine.2014.02.071.PubMedCrossRefGoogle Scholar
  18. Block SL, Nolan T, Sattler C, Barr E, Giacoletti KE, Marchant CD, Castellsagué X, Rusche SA, Lukac S, Bryan JT. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics. 2006;118:2135–45.PubMedCrossRefGoogle Scholar
  19. Bosch X. Former Peruvian government censured over sterilisations. BMJ. 2002;325:236.PubMedPubMedCentralCrossRefGoogle Scholar
  20. Bosch FX, de Sanjose S. Chapter 1: human papillomavirus and cervical cancer–burden and assessment of causality. J Natl Cancer Inst Monogr. 2003;2003:3–13.CrossRefGoogle Scholar
  21. Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol. 2002;55:244–65.PubMedPubMedCentralCrossRefGoogle Scholar
  22. Braaten T, Weiderpass E, Kumle M, Lund E. Explaining the socioeconomic variation in cancer risk in the Norwegian women and cancer study. Cancer Epidemiol Biomark Prev. 2005;14:2591–7. doi: 10.1158/1055-9965.epi-05-0345.CrossRefGoogle Scholar
  23. Braunack-Mayer A, Skinner SR, Collins J, Tooher R, Proeve C, O’Keefe M, Burgess T, Watson M, Marshall H. Ethical challenges in school-based immunization programs for adolescents: a qualitative study. Am J Public Health. 2015;105:1399–403. doi: 10.2105/AJPH.2014.302280.PubMedPubMedCentralCrossRefGoogle Scholar
  24. Brinth LS, Pors K, Theibel AC, Mehlsen J. Orthostatic intolerance and postural tachycardia syndrome as suspected adverse effects of vaccination against human papilloma virus. Vaccine. 2015;33:2602–5. doi: 10.1016/j.vaccine.2015.03.098.PubMedCrossRefGoogle Scholar
  25. Brinth L, Theibel AC, Pors K, Mehlsen J. Suspected side effects to the quadrivalent human papilloma vaccine. Dan Med J. 2015;62:A5064.PubMedGoogle Scholar
  26. Briones R, Nan X, Madden K, Waks L. When vaccines go viral: an analysis of HPV vaccine coverage on YouTube. Health Commun. 2012;27:478–85. doi: 10.1080/10410236.2011.610258.PubMedCrossRefGoogle Scholar
  27. Brisson M, Laprise JF, Drolet M, Van de Velde N, Franco EL, Kliewer EV, Ogilvie G, Deeks SL, Boily MC. Comparative cost-effectiveness of the quadrivalent and bivalent human papillomavirus vaccines: a transmission-dynamic modeling study. Vaccine. 2013;31:3863–71. doi: 10.1016/j.vaccine.2013.06.064.PubMedCrossRefGoogle Scholar
  28. Brisson M, van de Velde N, Franco EL, Drolet M, Boily MC. Incremental impact of adding boys to current human papillomavirus vaccination programs: role of herd immunity. J Infect Dis. 2011;204:372–6. doi: 10.1093/infdis/jir285.PubMedCrossRefGoogle Scholar
  29. Brown RE, Breugelmans JG, Theodoratou D, Benard S. Costs of detection and treatment of cervical cancer, cervical dysplasia and genital warts in the UK. Curr Med Res Opin. 2006;22:663–70. doi: 10.1185/030079906x99972.PubMedCrossRefGoogle Scholar
  30. Brown DR, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, Koutsky LA, Tay EH, Garcia P, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Steben M, Bosch FX, Dillner J, Joura EA, Kurman RJ, Majewski S, Munoz N, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan J, Lupinacci LC, Giacoletti KE, Sings HL, James M, Hesley TM, Barr E. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16–26 years. J Infect Dis. 2009;199:926–35. doi: 10.1086/597307.PubMedCrossRefGoogle Scholar
  31. Bulk S, Visser O, Rozendaal L, Verheijen RH, Meijer CJ. Cervical cancer in the Netherlands 1989-1998: decrease of squamous cell carcinoma in older women, increase of adenocarcinoma in younger women. Int J Cancer. 2005;113:1005–9. doi: 10.1002/ijc.20678.PubMedCrossRefGoogle Scholar
  32. Burger EA, Sy S, Nygard M, Kristiansen IS, Kim JJ. Prevention of HPV-related cancers in Norway: cost-effectiveness of expanding the HPV vaccination program to include pre-adolescent boys. PLoS One. 2014;9:e89974. doi: 10.1371/journal.pone.0089974.PubMedPubMedCentralCrossRefGoogle Scholar
  33. Canadian Immunization Committee. Recommendations for human papillomavirus immunization programs. Public Health Agency of Canada ed. Ottawa, ON: Public Health Agency of Canada; 2014. p. 52.Google Scholar
  34. Castellsague X, Giuliano AR, Goldstone S, Guevara A, Mogensen O, Palefsky JM, Group T, Shields C, Liu K, Maansson R, Luxembourg A, Kaplan SS. Immunogenicity and safety of the 9-valent HPV vaccine in men. Vaccine. 2015;33:6892–901. doi: 10.1016/j.vaccine.2015.06.088.PubMedCrossRefGoogle Scholar
  35. Cates JR, Shafer A, Carpentier FD, Reiter PL, Brewer NT, McRee A-L, Smith JS. How parents hear about human papillomavirus vaccine: implications for uptake. J Adolesc Health. 2010;47:305–8. doi: 10.1016/j.jadohealth.2010.04.003.PubMedPubMedCentralCrossRefGoogle Scholar
  36. CBC News. HPV vaccine refused by 2 Alberta Catholic school boards. 2008.Google Scholar
  37. Centers for Disease Control and Prevention. Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination. Recommendations of the immunization practices advisory committee (ACIP). MMWR Recomm Rep. 1991;40:1–25.Google Scholar
  38. Centers for Disease Control and Prevention. Results from the National Breast and cervical cancer early detection program, October 31, 1991–September 30, 1993. MMWR Morb Mortal Wkly Rep. 1994;43:530–4.Google Scholar
  39. Centers for Disease Control and Prevention. FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the advisory committee on immunization practices (ACIP). MMWR Morb Mortal Wkly Rep. 2010;59:630–2.Google Scholar
  40. Centers for Disease Control and Prevention. Recommendations on the use of quadrivalent human papillomavirus vaccine in males–advisory committee on immunization practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep. 2011;60:1705–8.Google Scholar
  41. Centers for Disease Control and Prevention. Cervical cancer screening among women by hysterectomy status and among women aged ≥65 years - United States, 2000–2010. MMWR Morb Mortal Wkly Rep. 2013;61:1043–7.Google Scholar
  42. Chao C, Klein NP, Velicer CM, Sy LS, Slezak JM, Takhar H, Ackerson B, Cheetham TC, Hansen J, Deosaransingh K, Emery M, Liaw KL, Jacobsen SJ. Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine. J Intern Med. 2012;271:193–203. doi: 10.1111/j.1365-2796.2011.02467.x.PubMedCrossRefGoogle Scholar
  43. Charo RA. Politics, parents, and prophylaxis — mandating HPV vaccination in the United States. N Engl J Med. 2007;356:1905–8. doi: 10.1056/NEJMp078054.PubMedCrossRefGoogle Scholar
  44. Chaturvedi AK. Beyond cervical cancer: burden of other HPV-related cancers among men and women. J Adolesc Health. 2010;46:S20–6. doi: 10.1016/j.jadohealth.2010.01.016.PubMedCrossRefGoogle Scholar
  45. Chaturvedi AK, Katki HA, Hildesheim A, Rodriguez AC, Quint W, Schiffman M, Van Doorn LJ, Porras C, Wacholder S, Gonzalez P, Sherman ME, Herrero R, Group CVT. Human papillomavirus infection with multiple types: pattern of coinfection and risk of cervical disease. J Infect Dis. 2011;203:910–20. doi: 10.1093/infdis/jiq139.PubMedPubMedCentralCrossRefGoogle Scholar
  46. Chesson HW, Ekwueme DU, Saraiya M, Dunne EF, Markowitz LE. The cost-effectiveness of male HPV vaccination in the United States. Vaccine. 2011;29:8443–50. doi: 10.1016/j.vaccine.2011.07.096.PubMedCrossRefGoogle Scholar
  47. Chesson HW, Ekwueme DU, Saraiya M, Watson M, Lowy DR, Markowitz LE. Estimates of the annual direct medical costs of the prevention and treatment of disease associated with human papillomavirus in the United States. Vaccine. 2012;30:6016–9. doi: 10.1016/j.vaccine.2012.07.056.PubMedCrossRefGoogle Scholar
  48. Cogliano V, Baan R, Straif K, Grosse Y, Secretan B, Ghissassi FE. Carcinogenicity of human papillomaviruses. Lancet Oncol. 2005;6:204. doi: 10.1016/S1470-2045(05)70086-3.PubMedCrossRefGoogle Scholar
  49. Colgrove J, Abiola S, Mello MM. HPV vaccination mandates — Lawmaking amid political and scientific controversy. N Engl J Med. 2010;363:785–91. doi: 10.1056/NEJMsr1003547.PubMedCrossRefGoogle Scholar
  50. Cope MB, Allison DB. White hat bias: examples of its presence in obesity research and a call for renewed commitment to faithfulness in research reporting. Int J Obes. 2009;34:84–8.CrossRefGoogle Scholar
  51. Cotter J. Last publicly funded school board to allow HPV vaccine: advocacy group: The Canadian Press., http://www.ctvnews.ca/health/last-publicly-funded-school-board-to-allow-hpv-vaccine-advocacy-group-1.1840330; 2014. Accessed 18 Feb 2016
  52. Crowe E, Pandeya N, Brotherton JM, Dobson AJ, Kisely S, Lambert SB, Whiteman DC. Effectiveness of quadrivalent human papillomavirus vaccine for the prevention of cervical abnormalities: case-control study nested within a population based screening programme in Australia. BMJ. 2014;348:g1458. doi: 10.1136/bmj.g1458.PubMedPubMedCentralCrossRefGoogle Scholar
  53. Cubie HA, Plumstead M, Zhang W, de Jesus O, Duncan LA, Stanley MA. Presence of antibodies to human papillomavirus virus-like particles (VLPs) in 11–13-year-old schoolgirls. J Med Virol. 1998;56:210–6. doi:10.1002/(SICI)1096-9071(199811)56:3<210::AID-JMV6>3.0.CO;2-A.PubMedCrossRefGoogle Scholar
  54. Daling JR, Madeleine MM, Johnson LG, Schwartz SM, Shera KA, Wurscher MA, Carter JJ, Porter PL, Galloway DA, McDougall JK. Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer. Cancer. 2004;101:270–80. doi: 10.1002/cncr.20365.PubMedCrossRefGoogle Scholar
  55. Darden PM, Thompson DM, Roberts JR, Hale JJ, Pope C, Naifeh M, Jacobson RM. Reasons for not vaccinating adolescents: National Immunization Survey of teens, 2008–2010. Pediatrics. 2013;131:645–51. doi: 10.1542/peds.2012-2384.PubMedCrossRefGoogle Scholar
  56. David MP, Van Herck K, Hardt K, Tibaldi F, Dubin G, Descamps D, Van Damme P. Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: modeling of sustained antibody responses. Gynecol Oncol. 2009;115:S1–6. doi: 10.1016/j.ygyno.2009.01.011.PubMedCrossRefGoogle Scholar
  57. Day PM, Kines RC, Thompson CD, Jagu S, Roden RB, Lowy DR, Schiller JT. In vivo mechanisms of vaccine-induced protection against HPV infection. Cell Host Microbe. 2010;8:260–70. doi: 10.1016/j.chom.2010.08.003.PubMedPubMedCentralCrossRefGoogle Scholar
  58. De Vuyst H, Clifford GM, Nascimento MC, Madeleine MM, Franceschi S. Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. Int J Cancer. 2009;124:1626–36. doi: 10.1002/ijc.24116.PubMedCrossRefGoogle Scholar
  59. Dempsey AF, Zimet GD, Davis RL, Koutsky L. Factors that are associated with parental acceptance of human papillomavirus vaccines: a randomized intervention study of written information about HPV. Pediatrics. 2006;117:1486–93.PubMedCrossRefGoogle Scholar
  60. Descamps D, Hardt K, Spiessens B, Izurieta P, Verstraeten T, Breuer T, Dubin G. Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: a pooled analysis of 11 clinical trials. Hum Vaccin. 2009;5:332–40.PubMedCrossRefGoogle Scholar
  61. DeStefano F, Thompson WW. MMR vaccine and autism: an update of the scientific evidence. Expert Rev Vaccines. 2004;3:19–22.PubMedCrossRefGoogle Scholar
  62. Dickinson JA, Stankiewicz A, Popadiuk C, Pogany L, Onysko J, Miller AB. Reduced cervical cancer incidence and mortality in Canada: national data from 1932 to 2006. BMC Public Health. 2012;12:992. doi: 10.1186/1471-2458-12-992.PubMedPubMedCentralCrossRefGoogle Scholar
  63. Dobson SR, McNeil S, Dionne M, Dawar M, Ogilvie G, Krajden M, Sauvageau C, Scheifele DW, Kollmann TR, Halperin SA. Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial. JAMA. 2013;309:1793–802.PubMedCrossRefGoogle Scholar
  64. Donegan K, Beau-Lejdstrom R, King B, Seabroke S, Thomson A, Bryan P. Bivalent human papillomavirus vaccine and the risk of fatigue syndromes in girls in the UK. Vaccine. 2013;31:4961–7. doi: 10.1016/j.vaccine.2013.08.024.PubMedCrossRefGoogle Scholar
  65. Drolet M, Benard E, Boily MC, Ali H, Baandrup L, Bauer H, Beddows S, Brisson J, Brotherton JM, Cummings T, Donovan B, Fairley CK, Flagg EW, Johnson AM, Kahn JA, Kavanagh K, Kjaer SK, Kliewer EV, Lemieux-Mellouki P, Markowitz L, Mboup A, Mesher D, Niccolai L, Oliphant J, Pollock KG, Soldan K, Sonnenberg P, Tabrizi SN, Tanton C, Brisson M. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis. 2015;15:565–80. doi: 10.1016/s1473-3099(14)71073-4.PubMedPubMedCentralCrossRefGoogle Scholar
  66. D'Souza G, Kreimer AR, Viscidi R, Pawlita M, Fakhry C, Koch WM, Westra WH, Gillison ML. Case–control study of human papillomavirus and oropharyngeal cancer. N Engl J Med. 2007;356:1944–56. doi: 10.1056/NEJMoa065497.PubMedCrossRefGoogle Scholar
  67. Dunn AG, Leask J, Zhou X, Mandl KD, Coiera E. Associations between exposure to and expression of negative opinions about human papillomavirus vaccines on social media: an observational study. J Med Internet Res. 2015;17:e144. doi: 10.2196/jmir.4343.PubMedPubMedCentralCrossRefGoogle Scholar
  68. Dyer O. Canadian academic’s call for moratorium on HPV vaccine sparks controversy. BMJ. 2015;351:h5692. doi: 10.1136/bmj.h5692.PubMedCrossRefGoogle Scholar
  69. Einstein MH, Baron M, Levin MJ, Chatterjee A, Fox B, Scholar S, Rosen J, Chakhtoura N, Meric D, Dessy FJ, Datta SK, Descamps D, Dubin G, Group HPVS. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12-24 in a phase III randomized study of healthy women aged 18-45 years. Hum Vaccin. 2011;7:1343–58. doi: 10.4161/hv.7.12.18281.PubMedPubMedCentralCrossRefGoogle Scholar
  70. El Amin AN, Parra MT, Kim-Farley R. Ethical issues concerning vaccination requirements. Public Health Rev. 2012;34:14.CrossRefGoogle Scholar
  71. Elam-Evans LD, Yankey D, Jeyarajah J, Singleton JA, Curtis RC, MacNeil J, Hariri S. National, regional, state, and selected local area vaccination coverage among adolescents aged 13–17 years - United States, 2013. MMWR Morb Mortal Wkly Rep. 2014;63:625–33.PubMedGoogle Scholar
  72. Elbasha EH, Dasbach EJ, Insinga RP. Model for assessing human papillomavirus vaccination strategies. Emerging Infectious Disease journal. 2007;13:28. doi: 10.3201/eid1301.060438.CrossRefGoogle Scholar
  73. Elbasha EH, Galvani AP. Vaccination against multiple HPV types. Math Biosci. 2005;197:88–117. doi: 10.1016/j.mbs.2005.05.004.PubMedCrossRefGoogle Scholar
  74. Ferris D, Samakoses R, Block SL, Lazcano-Ponce E, Restrepo JA, Reisinger KS, Mehlsen J, Chatterjee A, Iversen OE, Sings HL, Shou Q, Sausser TA, Saah A. Long-term study of a quadrivalent human papillomavirus vaccine. Pediatrics. 2014;134:e657–65. doi: 10.1542/peds.2013-4144.PubMedCrossRefGoogle Scholar
  75. Fesenfeld M, Hutubessy R, Jit M. Cost-effectiveness of human papillomavirus vaccination in low and middle income countries: a systematic review. Vaccine. 2013;31:3786–804. doi: 10.1016/j.vaccine.2013.06.060.PubMedCrossRefGoogle Scholar
  76. Food and Drug Administration. VRBPAC Background Document: Gardasil™ HPV Quadrivalent Vaccine, 18 May 2006. In: VRBPAC Meeting; 2006.Google Scholar
  77. Forster AS, Marlow LAV, Stephenson J, Wardle J, Waller J. Human papillomavirus vaccination and sexual behaviour: cross-sectional and longitudinal surveys conducted in England. Vaccine. 2012;30:4939–44. doi: 10.1016/j.vaccine.2012.05.053.PubMedCrossRefGoogle Scholar
  78. Forster A, Wardle J, Stephenson J, Waller J. Passport to promiscuity or lifesaver: press coverage of HPV vaccination and risky sexual behavior. J Health Commun. 2010;15:205–17. doi: 10.1080/10810730903528066.PubMedCrossRefGoogle Scholar
  79. Franco EL, Cuzick J, Hildesheim A, de Sanjose S. Chapter 20: issues in planning cervical cancer screening in the era of HPV vaccination. Vaccine. 2006;24(Suppl 3):S3/171–7. doi: 10.1016/j.vaccine.2006.05.061.Google Scholar
  80. Franco EL, de Sanjose S, Broker TR, Stanley MA, Chevarie-Davis M, Isidean SD, Schiffman M. Human papillomavirus and cancer prevention: gaps in knowledge and prospects for research, policy, and advocacy. Vaccine. 2012;30(Suppl 5):F175–82. doi: 10.1016/j.vaccine.2012.06.092.PubMedPubMedCentralCrossRefGoogle Scholar
  81. Franco EL, Mahmud SM, Tota J, Ferenczy A, Coutlee F. The expected impact of HPV vaccination on the accuracy of cervical cancer screening: the need for a paradigm change. Arch Med Res. 2009;40:478–85. doi: 10.1016/j.arcmed.2009.06.003.PubMedCrossRefGoogle Scholar
  82. Franco EL, Rohan TE, Villa LL. Epidemiologic evidence and human papillomavirus infection as a necessary cause of cervical cancer. J Natl Cancer Inst. 1999;91:506–11.PubMedCrossRefGoogle Scholar
  83. Fraser C, Tomassini JE, Xi L, Golm G, Watson M, Giuliano AR, Barr E, Ault KA. Modeling the long-term antibody response of a human papillomavirus (HPV) virus-like particle (VLP) type 16 prophylactic vaccine. Vaccine. 2007;25:4324–33. doi: 10.1016/j.vaccine.2007.02.069.PubMedCrossRefGoogle Scholar
  84. Future II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356:1915–27. doi: 10.1056/NEJMoa061741.CrossRefGoogle Scholar
  85. Gamble HL, Klosky JL, Parra GR, Randolph ME. Factors influencing familial decision-making regarding human papillomavirus vaccination. J Pediatr Psychol. 2010;35:704–15. doi: 10.1093/jpepsy/jsp108.PubMedCrossRefGoogle Scholar
  86. Garland SM, Ault KA, Gall SA, Paavonen J, Sings HL, Ciprero KL, Saah A, Marino D, Ryan D, Radley D, Zhou H, Haupt RM, Garner EIO. Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18 vaccine: a combined analysis of five randomized controlled trials. Obstet Gynecol. 2009;114:1179–88. doi: 10.1097/AOG.0b013e3181c2ca21.PubMedCrossRefGoogle Scholar
  87. Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, Tang GW, Ferris DG, Steben M, Bryan J, Taddeo FJ, Railkar R, Esser MT, Sings HL, Nelson M, Boslego J, Sattler C, Barr E, Koutsky LA, Females United to Unilaterally Reduce Endo/Ectocervical Disease II. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007;356:1928–43. doi: 10.1056/NEJMoa061760.PubMedCrossRefGoogle Scholar
  88. Gee J, Naleway A, Shui I, Baggs J, Yin R, Li R, Kulldorff M, Lewis E, Fireman B, Daley MF, Klein NP, Weintraub ES. Monitoring the safety of quadrivalent human papillomavirus vaccine: findings from the vaccine safety datalink. Vaccine. 2011;29:8279–84. doi: 10.1016/j.vaccine.2011.08.106.PubMedCrossRefGoogle Scholar
  89. Gefenaite G, Smit M, Nijman HW, Tami A, Drijfhout IH, Pascal A, Postma MJ, Wolters BA, van Delden JJM, Wilschut JC, Hak E. Comparatively low attendance during human papillomavirus catch-up vaccination among teenage girls in the Netherlands: insights from a behavioral survey among parents. BMC Public Health. 2012;12:498. doi: 10.1186/1471-2458-12-498.PubMedPubMedCentralCrossRefGoogle Scholar
  90. Giuliano AR, Isaacs-Soriano K, Torres BN, Abrahamsen M, Ingles DJ, Sirak BA, Quiterio M, Lazcano-Ponce E. Immunogenicity and safety of Gardasil among mid-adult aged men (27–45 years)—the MAM study. Vaccine. 2015;33:5640–6. doi: 10.1016/j.vaccine.2015.08.072.PubMedCrossRefGoogle Scholar
  91. Giuliano AR, Palefsky JM, Goldstone S, Moreira ED, Penny ME, Aranda C, Vardas E, Moi H, Jessen H, Hillman R, Chang Y-H, Ferris D, Rouleau D, Bryan J, Marshall JB, Vuocolo S, Barr E, Radley D, Haupt RM, Guris D. Efficacy of Quadrivalent HPV vaccine against HPV infection and disease in males. N Engl J Med. 2011;364:401–11. doi: 10.1056/NEJMoa0909537.PubMedPubMedCentralCrossRefGoogle Scholar
  92. Global Advisory Committee on Vaccine Safety. Statement on the continued safety of HPV vaccination. Geneva; 2014.Google Scholar
  93. Global Advisory Committee on Vaccine Safety. Global advisory committee on vaccine safety: statement on safety of HPV vaccines. Geneva: World Health Organization; 2015.Google Scholar
  94. Goldie SJ, O'Shea M, Campos NG, Diaz M, Sweet S, Kim S-Y. Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries. Vaccine. 2008;26:4080–93. doi: 10.1016/j.vaccine.2008.04.053.PubMedCrossRefGoogle Scholar
  95. Gray JAM. Postmodern medicine. The. Lancet. 1999;354:1550–3. doi: 10.1016/S0140-6736(98)08482-7.PubMedCrossRefGoogle Scholar
  96. Grimaldi-Bensouda L, Guillemot D, Godeau B, Bénichou J, Lebrun-Frenay C, Papeix C, Labauge P, Berquin P, Penfornis A, Benhamou PY, Nicolino M, Simon A, Viallard JF, Costedoat-Chalumeau N, Courcoux MF, Pondarré C, Hilliquin P, Chatelus E, Foltz V, Guillaume S, Rossignol M, Abenhaim L, The P-AIDSG. Autoimmune disorders and quadrivalent human papillomavirus vaccination of young female subjects. J Intern Med. 2014;275:398–408. doi: 10.1111/joim.12155.PubMedCrossRefGoogle Scholar
  97. Gruber N, Shoenfeld Y. A link between human papilloma virus vaccination and primary ovarian insufficiency: current analysis. Curr Opin Obstet Gynecol. 2015;27:265–70. doi: 10.1097/gco.0000000000000183.PubMedCrossRefGoogle Scholar
  98. Guan P, Howell-Jones R, Li N, Bruni L, de Sanjose S, Franceschi S, Clifford GM. Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer. Int J Cancer. 2012;131:2349–59. doi: 10.1002/ijc.27485.PubMedCrossRefGoogle Scholar
  99. Guichon JR, Mitchell I, Buffler P, Caplan A. Citizen intervention in a religious ban on in-school HPV vaccine administration in Calgary, Canada. Prev Med. 2013;57:409–13. doi: 10.1016/j.ypmed.2013.06.005.PubMedCrossRefGoogle Scholar
  100. Gustafsson L, Ponten J, Zack M, Adami HO. International incidence rates of invasive cervical cancer after introduction of cytological screening. Cancer Causes Control. 1997;8:755–63.PubMedCrossRefGoogle Scholar
  101. Habbema D, De Kok IM, Brown ML. Cervical cancer screening in the United States and the Netherlands: a tale of two countries. Milbank Q. 2012;90:5–37. doi: 10.1111/j.1468-0009.2011.00652.x.PubMedPubMedCentralCrossRefGoogle Scholar
  102. Habel MA, Liddon N, Stryker JE. The HPV vaccine: a content analysis of online news stories. J Womens Health (Larchmt). 2009;18:401–7. doi: 10.1089/jwh.2008.0920.CrossRefGoogle Scholar
  103. Haber G, Malow RM, Zimet GD. The HPV vaccine mandate controversy. J Pediatr Adolesc Gynecol. 2007;20:325–31. doi: 10.1016/j.jpag.2007.03.101.PubMedCrossRefGoogle Scholar
  104. Hanley SJ, Yoshioka E, Ito Y, Kishi R. HPV vaccination crisis in Japan. Lancet. 2015;385:2571. doi: 10.1016/S0140-6736(15)61152-7.PubMedCrossRefGoogle Scholar
  105. Hansen BT, Campbell S, Burger E, Nygård M. Correlates of HPV vaccine uptake in school-based routine vaccination of preadolescent girls in Norway: a register-based study of 90,000 girls and their parents. Prev Med. 2015;77:4–10. doi: 10.1016/j.ypmed.2015.04.024.PubMedCrossRefGoogle Scholar
  106. Hanson CM, Eckert L, Bloem P, Cernuschi T. Gavi HPV programs: application to implementation. Vaccine. 2015;3:408–19. doi: 10.3390/vaccines3020408.CrossRefGoogle Scholar
  107. Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, Jenkins D, Schuind A, Costa Clemens SA, Dubin G, Group HPVVS. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet. 2006;367:1247–55. doi: 10.1016/S0140-6736(06)68439-0.PubMedCrossRefGoogle Scholar
  108. Harper DM, Nieminen P, Paavonen J, Lehtinen M. Cervical cancer incidence can increase despite HPV vaccination. Lancet Infect Dis. 2010;10:594–5. doi: 10.1016/S1473-3099(10)70182-1.PubMedCrossRefGoogle Scholar
  109. Hendry M, Lewis R, Clements A, Damery S, Wilkinson C. “HPV? Never heard of it!”: a systematic review of girls' and parents' information needs, views and preferences about human papillomavirus vaccination. Vaccine. 2013;31:5152–67. doi: 10.1016/j.vaccine.2013.08.091.PubMedCrossRefGoogle Scholar
  110. Herrero R, González P, Markowitz LE. Present status of human papillomavirus vaccine development and implementation. Lancet Oncol. 2015;16:e206–16. doi: 10.1016/S1470-2045(14)70481-4.PubMedCrossRefGoogle Scholar
  111. Hildesheim A, Gonzalez P, Kreimer AR, Wacholder S, Schussler J, Rodriguez AC, Porras C, Schiffman M, Sidawy M, Schiller JT, Lowy DR, Herrero R. Impact of human papillomavirus (HPV) 16 and 18 vaccination on prevalent infections and rates of cervical lesions after excisional treatment. Am J Obstet Gynecol. 2016;215:212.e1–212.e15. doi: 10.1016/j.ajog.2016.02.021.CrossRefGoogle Scholar
  112. Hildesheim A, Herrero R, Wacholder S, Rodriguez AC, Solomon D, Bratti MC, Schiller JT, Gonzalez P, Dubin G, Porras C, Jimenez SE, Lowy DR, Costa Rican HPVVTG. Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA. 2007;298:743–53. doi: 10.1001/jama.298.7.743.PubMedCrossRefGoogle Scholar
  113. Hildesheim A, Wacholder S, Catteau G, Struyf F, Dubin G, Herrero R, CVTG. Efficacy of the HPV-16/18 vaccine: final according to protocol results from the blinded phase of the randomized Costa Rica HPV-16/18 vaccine trial. Vaccine. 2014;32:5087–97. doi: 10.1016/j.vaccine.2014.06.038.PubMedPubMedCentralCrossRefGoogle Scholar
  114. Hughes A, Mesher D, White J, Soldan K. Coverage of the English national human papillomavirus (HPV) immunisation programme among 12 to 17 year-old females by area-level deprivation score, England, 2008 to 2011. Euro Surveill. 2014;19:20677.PubMedCrossRefGoogle Scholar
  115. Inglis S, Shaw A, Koenig S. Chapter 11: HPV vaccines: Commercial Research & Development. Vaccine. 2006;24(Suppl 3):S99–S105. doi: 10.1016/j.vaccine.2006.05.119.CrossRefGoogle Scholar
  116. Janerich DT, Hadjimichael O, Schwartz PE, Lowell DM, Meigs JW, Merino MJ, Flannery JT, Polednak AP. The screening histories of women with invasive cervical cancer, Connecticut. Am J Public Health. 1995;85:791–4.PubMedPubMedCentralCrossRefGoogle Scholar
  117. Jit M, Brisson M, Portnoy A, Hutubessy R. Cost-effectiveness of female human papillomavirus vaccination in 179 countries: a PRIME modelling study. Lancet Glob Health. 2014;2:e406–14. doi: 10.1016/s2214-109x(14)70237-2.PubMedCrossRefGoogle Scholar
  118. Jit M, Choi YH, Edmunds WJ. Economic evaluation of human papillomavirus vaccination in the United Kingdom. BMJ. 2008;337:a769.PubMedPubMedCentralCrossRefGoogle Scholar
  119. Joura EA, Giuliano AR, Iversen O-E, Bouchard C, Mao C, Mehlsen J, Moreira ED, Ngan Y, Petersen LK, Lazcano-Ponce E, Pitisuttithum P, Restrepo JA, Stuart G, Woelber L, Yang YC, Cuzick J, Garland SM, Huh W, Kjaer SK, Bautista OM, Chan ISF, Chen J, Gesser R, Moeller E, Ritter M, Vuocolo S, Luxembourg A. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med. 2015;372:711–23. doi: 10.1056/NEJMoa1405044.PubMedCrossRefGoogle Scholar
  120. Joura EA, Leodolter S, Hernandez-Avila M, Wheeler CM, Perez G, Koutsky LA, Garland SM, Harper DM, Tang GW, Ferris DG, Steben M, Jones RW, Bryan J, Taddeo FJ, Bautista OM, Esser MT, Sings HL, Nelson M, Boslego JW, Sattler C, Barr E, Paavonen J. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet. 2007;369:1693–702. doi: 10.1016/s0140-6736(07)60777-6.PubMedCrossRefGoogle Scholar
  121. Kahn JA, Brown DR, Ding L, Widdice LE, Shew ML, Glynn S, Bernstein DI. Vaccine-type human papillomavirus and evidence of herd protection after vaccine introduction. Pediatrics. 2012;130:e249–56. doi: 10.1542/peds.2011-3587.PubMedPubMedCentralCrossRefGoogle Scholar
  122. Kane MA, Serrano B, de Sanjosé S, Wittet S. Implementation of human papillomavirus immunization in the developing world. Vaccine. 2012;30(Suppl 5):F192–200. doi: 10.1016/j.vaccine.2012.06.075.PubMedCrossRefGoogle Scholar
  123. Kata A. A postmodern Pandora's box: anti-vaccination misinformation on the internet. Vaccine. 2010;28:1709–16. doi: 10.1016/j.vaccine.2009.12.022.PubMedCrossRefGoogle Scholar
  124. Khan MJ, Castle PE, Lorincz AT, Wacholder S, Sherman M, Scott DR, Rush BB, Glass AG, Schiffman M. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst. 2005;97:1072–9. doi: 10.1093/jnci/dji187.PubMedCrossRefGoogle Scholar
  125. Kim JJ. A cost-effectiveness analysis of targeted HPV vaccination of men who have sex with men in the United States. Lancet Infect Dis. 2010;10:845–52. doi: 10.1016/S1473-3099(10)70219-X.PubMedPubMedCentralCrossRefGoogle Scholar
  126. Kim JJ, Andres-Beck B, Goldie SJ. The value of including boys in an HPV vaccination programme: a cost-effectiveness analysis in a low-resource setting. Br J Cancer. 2007;97:1322–8. doi: 10.1038/sj.bjc.6604023.PubMedPubMedCentralCrossRefGoogle Scholar
  127. Kim JJ, Goldie SJ. Health and economic implications of HPV vaccination in the United States. N Engl J Med. 2008;359:821–32. doi: 10.1056/NEJMsa0707052.PubMedPubMedCentralCrossRefGoogle Scholar
  128. Kirschner B, Poll S, Rygaard C, Wahlin A, Junge J. Screening history in women with cervical cancer in a Danish population-based screening program. Gynecol Oncol. 2011;120:68–72. doi: 10.1016/j.ygyno.2010.09.021.PubMedCrossRefGoogle Scholar
  129. Kjaer SK, Frederiksen K, Munk C, Iftner T. Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. J Natl Cancer Inst. 2010;102:1478–88. doi: 10.1093/jnci/djq356.PubMedPubMedCentralCrossRefGoogle Scholar
  130. Konno R, Hanley J, Miyagi E. Comparison of safety statements from national authorities and international health bodies for HPV vaccine. EUROGIN 2015, Sevilla, Spain; 2015a.Google Scholar
  131. Konno R, Hanley J, Miyagi E. HPV vaccine concerns in Japan–social and political background. EUROGIN 2015, Sevilla, Spain; 2015b.Google Scholar
  132. Konno R, Sasagawa T, Fukuda T, Van Kriekinge G, Demarteau N. Cost-effectiveness analysis of prophylactic cervical cancer vaccination in Japanese women. Int J Gynecol Cancer. 2010;20:385–92. doi: 10.1111/IGC.0b013e3181d189b8.PubMedCrossRefGoogle Scholar
  133. Kreimer AR, Clifford GM, Boyle P, Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomark Prev. 2005;14:467–75. doi: 10.1158/1055-9965.EPI-04-0551.CrossRefGoogle Scholar
  134. Kyrgiou M, Koliopoulos G, Martin-Hirsch P, Arbyn M, Prendiville W, Paraskevaidis E. Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis. Lancet. 2006;367:489–98. doi: 10.1016/S0140-6736(06)68181-6.PubMedCrossRefGoogle Scholar
  135. Kyrgiou M, Mitra A, Arbyn M, Stasinou SM, Martin-Hirsch P, Bennett P, Paraskevaidis E. Fertility and early pregnancy outcomes after treatment for cervical intraepithelial neoplasia: systematic review and meta-analysis. BMJ. 2014;349:g6192. doi: 10.1136/bmj.g6192.PubMedPubMedCentralCrossRefGoogle Scholar
  136. La Vincente SF, Mielnik D, Jenkins K, Bingwor F, Volavola L, Marshall H, Druavesi P, Russell FM, Lokuge K, Mulholland EK. Implementation of a national school-based human papillomavirus (HPV) vaccine campaign in Fiji: knowledge, vaccine acceptability and information needs of parents. BMC Public Health. 2015;15:1257. doi: 10.1186/s12889-015-2579-3.PubMedPubMedCentralCrossRefGoogle Scholar
  137. Laprise JF, Drolet M, Boily MC, Jit M, Sauvageau C, Franco EL, Lemieux-Mellouki P, Malagon T, Brisson M. Comparing the cost-effectiveness of two- and three-dose schedules of human papillomavirus vaccination: a transmission-dynamic modelling study. Vaccine. 2014;32:5845–53. doi: 10.1016/j.vaccine.2014.07.099.PubMedCrossRefGoogle Scholar
  138. Larson HJ, Brocard P, Garnett G. The India HPV-vaccine suspension. Lancet. 2010;376:572–3. doi: 10.1016/S0140-6736(10)60881-1.PubMedCrossRefGoogle Scholar
  139. Leyden WA, Manos MM, Geiger AM, Weinmann S, Mouchawar J, Bischoff K, Yood MU, Gilbert J, Taplin SH. Cervical cancer in women with comprehensive health care access: attributable factors in the screening process. J Natl Cancer Inst. 2005;97:675–83. doi: 10.1093/jnci/dji115.PubMedCrossRefGoogle Scholar
  140. Li N, Franceschi S, Howell-Jones R, Snijders PJ, Clifford GM. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: variation by geographical region, histological type and year of publication. Int J Cancer. 2011;128:927–35. doi: 10.1002/ijc.25396.PubMedCrossRefGoogle Scholar
  141. Lindblad EB. Aluminium adjuvants—in retrospect and prospect. Vaccine. 2004;22:3658–68. doi: 10.1016/j.vaccine.2004.03.032.PubMedCrossRefGoogle Scholar
  142. Lippman A, Boscoe M, Scurfield C. Do you approve of spending $300 million on HPV vaccination?: NO. Can Fam Physician. 2008;54:175–7.PubMedPubMedCentralGoogle Scholar
  143. Lippman A, Cattapan A, Holloway K. Evidence and the marketing of the HPV vaccine. In: Impact Ethics. https://impactethics.ca/2014/11/04/evidence-and-the-marketing-of-the-hpv-vaccine/. 2014. Accessed 22 Feb 2016.
  144. Lippman A, Melnychuk R, Shimmin C, Boscoe M. Human papillomavirus, vaccines and women's health: questions and cautions. CMAJ. 2007;177:484–7. doi: 10.1503/cmaj.070944.PubMedPubMedCentralCrossRefGoogle Scholar
  145. Lonnberg S, Anttila A, Luostarinen T, Nieminen P. Age-specific effectiveness of the Finnish cervical cancer screening programme. Cancer Epidemiol Biomark Prev. 2012;21:1354–61. doi: 10.1158/1055-9965.epi-12-0162.CrossRefGoogle Scholar
  146. Lönnberg S, Hansen BT, Haldorsen T, Campbell S, Schee K, Nygård M. Cervical cancer prevented by screening: long-term incidence trends by morphology in Norway. Int J Cancer. 2015;137:1758–64. doi: 10.1002/ijc.29541.PubMedCrossRefGoogle Scholar
  147. Luyten J, Engelen B, Beutels P. The sexual ethics of HPV vaccination for boys. HEC Forum. 2014;26:27–42. doi: 10.1007/s10730-013-9219-z.PubMedCrossRefGoogle Scholar
  148. Machii R, Saito H. Time trends in cervical cancer screening rates in the OECD countries. Jpn J Clin Oncol. 2011;41:731–2. doi: 10.1093/jjco/hyr058.PubMedCrossRefGoogle Scholar
  149. Madden K, Nan X, Briones R, Waks L. Sorting through search results: a content analysis of HPV vaccine information online. Vaccine. 2012;30:3741–6. doi: 10.1016/j.vaccine.2011.10.025.PubMedCrossRefGoogle Scholar
  150. Mah CL, Deber RB, Guttmann A, McGeer A, Krahn M. Another look at the human papillomavirus vaccine experience in Canada. Am J Public Health. 2011;101:1850–7. doi: 10.2105/ajph.2011.300205.PubMedPubMedCentralCrossRefGoogle Scholar
  151. Mahmud SM, Kliewer EV, Lambert P, Bozat-Emre S, Demers AA. Effectiveness of the quadrivalent human papillomavirus vaccine against cervical dysplasia in manitoba, Canada. J Clin Oncol. 2014;32:438–43. doi: 10.1200/JCO.2013.52.4645.PubMedCrossRefGoogle Scholar
  152. Malagon T, Drolet M, Boily MC, Laprise JF, Brisson M. Changing inequalities in cervical cancer: modeling the impact of vaccine uptake, vaccine herd effects, and cervical cancer screening in the post-vaccination era. Cancer Epidemiol Biomark Prev. 2015;24:276–85. doi: 10.1158/1055-9965.epi-14-1052.CrossRefGoogle Scholar
  153. Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER. Quadrivalent human papillomavirus vaccine: recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep. 2007;56:1–24.PubMedGoogle Scholar
  154. Markowitz LE, Hariri S, Lin C, Dunne EF, Steinau M, McQuillan G, Unger ER. Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and nutrition examination surveys, 2003–2010. J Infect Dis. 2013;208:385–93. doi: 10.1093/infdis/jit192.PubMedCrossRefGoogle Scholar
  155. Markowitz LE, Liu G, Hariri S, Steinau M, Dunne EF, Unger ER. Prevalence of HPV after introduction of the vaccination program in the United States. Pediatrics. 2016;137:e20151968. doi: 10.1542/peds.2015-1968.PubMedCrossRefGoogle Scholar
  156. de Martel C, Ferlay J, Franceschi S, Vignat J, Bray F, Forman D, Plummer M. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol. 2012;13:607–15. doi: 10.1016/S1470-2045(12)70137-7.PubMedCrossRefGoogle Scholar
  157. McQueen M. HPV vaccines are not the answer! Toronto, ON: Canadian Catholic Bioethics Institute; 2007.Google Scholar
  158. Mullins T, Zimet GD, Rosenthal SL, et al. Adolescent perceptions of risk and need for safer sexual behaviors after first human papillomavirus vaccination. Arch Pediatr Adolesc Med. 2012;166:82–8. doi: 10.1001/archpediatrics.2011.186.PubMedPubMedCentralCrossRefGoogle Scholar
  159. Muñoz N. Human papillomavirus and cancer: the epidemiological evidence. J Clin Virol. 2000;19:1–5. doi: 10.1016/S1386-6532(00)00125-6.PubMedCrossRefGoogle Scholar
  160. Muñoz N, Castellsagué X, de González AB, Gissmann L. Chapter 1: HPV in the etiology of human cancer. Vaccine. 2006;24(Suppl 3):S1–S10. doi: 10.1016/j.vaccine.2006.05.115.CrossRefGoogle Scholar
  161. Munoz N, Manalastas R Jr, Pitisuttithum P, Tresukosol D, Monsonego J, Ault K, Clavel C, Luna J, Myers E, Hood S, Bautista O, Bryan J, Taddeo FJ, Esser MT, Vuocolo S, Haupt RM, Barr E, Saah A. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24–45 years: a randomised, double-blind trial. Lancet. 2009;373:1949–57. doi: 10.1016/s0140-6736(09)60691-7.PubMedCrossRefGoogle Scholar
  162. Musto R, Siever JE, Johnston JC, Seidel J, Rose MS, McNeil DA. Social equity in human papillomavirus vaccination: a natural experiment in Calgary Canada. BMC Public Health. 2013;13:640. doi: 10.1186/1471-2458-13-640.PubMedPubMedCentralCrossRefGoogle Scholar
  163. National Advisory Committee on Immunization. Update On Human Papillomavirus (HPV) Vaccines. Canada Communicable Disease Report, vol 38. Public Health Agency of Canada; 2012.Google Scholar
  164. Nature Biotechnology. Flogging Gardasil. Nat Biotech. 2007;25:261.CrossRefGoogle Scholar
  165. Naud P, Roteli-Martins CM, Teixeira JC, Borba P, Sanchez N, Geeraerts B, Zahaf T, Descamps D. HPV-16/18 Vaccine: sustained immunogenicity and efficacy up to 9.4 years. In: 27th international papillomavirus conference and clinical workshop, Berlin, Germany, 2011.Google Scholar
  166. New Zealand Ministry of Health. The HPV (Human Papillomavirus) immunisation programme: national implementation strategic overview. 2008.Google Scholar
  167. O'Connor M, Gallagher P, Waller J, Martin CM, O'Leary JJ, Sharp L. Adverse psychological outcomes following colposcopy and related procedures: a systematic review. BJOG. 2016;123:24–38. doi: 10.1111/1471-0528.13462.PubMedCrossRefGoogle Scholar
  168. Ogilvie G, Anderson M, Marra F, McNeil S, Pielak K, Dawar M, McIvor M, Ehlen T, Dobson S, Money D, Patrick DM, Naus M. A population-based evaluation of a publicly funded, school-based HPV vaccine program in British Columbia, Canada: parental factors associated with HPV vaccine receipt. PLoS Med. 2010;7:e1000270. doi: 10.1371/journal.pmed.1000270.PubMedPubMedCentralCrossRefGoogle Scholar
  169. Ojha RP, Jackson BE, Tota JE, Offutt-Powell TN, Singh KP, Bae S. Guillain–Barre syndrome following quadrivalent human papillomavirus vaccination among vaccine-eligible individuals in the United States. Hum Vaccin Immunother. 2014;10:232–7. doi: 10.4161/hv.26292.PubMedCrossRefGoogle Scholar
  170. Olsen J, Jepsen MR. Human papillomavirus transmission and cost-effectiveness of introducing quadrivalent HPV vaccination in Denmark. Int J Technol Assess Health Care. 2010;26:183–91. doi: 10.1017/s0266462310000085.PubMedCrossRefGoogle Scholar
  171. Opel DJ, Diekema DS, Marcuse EK. A critique of criteria for evaluating vaccines for inclusion in mandatory school immunization programs. Pediatrics. 2008;122:e504–10. doi: 10.1542/peds.2007-3218.PubMedCrossRefGoogle Scholar
  172. Ostensson E, Froberg M, Leval A, Hellstrom AC, Backlund M, Zethraeus N, Andersson S. Cost of preventing, managing, and treating human papillomavirus (HPV)-related diseases in Sweden before the introduction of Quadrivalent HPV vaccination. PLoS One. 2015;10:e0139062. doi: 10.1371/journal.pone.0139062.PubMedPubMedCentralCrossRefGoogle Scholar
  173. Paavonen J, Naud P, Salmeron J, Wheeler CM, Chow SN, Apter D, Kitchener H, Castellsague X, Teixeira JC, Skinner SR, Hedrick J, Jaisamrarn U, Limson G, Garland S, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, Bosch FX, Jenkins D, Hardt K, Zahaf T, Descamps D, Struyf F, Lehtinen M, Dubin G, Group HPS. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet. 2009;374:301–14. doi: 10.1016/S0140-6736(09)61248-4.PubMedCrossRefGoogle Scholar
  174. Pearson AL, Kvizhinadze G, Wilson N, Smith M, Canfell K, Blakely T. Is expanding HPV vaccination programs to include school-aged boys likely to be value-for-money: a cost-utility analysis in a country with an existing school-girl program. BMC Infect Dis. 2014;14:351. doi: 10.1186/1471-2334-14-351.PubMedPubMedCentralCrossRefGoogle Scholar
  175. Pharmacovigilance Risk Assessment Committee. HPV vaccines Article-20 procedure - Assessment report. London: European Medicines Agency; 2015.Google Scholar
  176. Polonijo AN, Carpiano RM. Social inequalities in adolescent human papillomavirus (HPV) vaccination: a test of fundamental cause theory. Soc Sci Med. 2013;82:115–25. doi: 10.1016/j.socscimed.2012.12.020.PubMedCrossRefGoogle Scholar
  177. Poole T, Goodyear-Smith F, Petousis-Harris H, Desmond N, Exeter D, Pointon L, Jayasinha R. Human papillomavirus vaccination in Auckland: reducing ethnic and socioeconomic inequities. Vaccine. 2012;31:84–8. doi: 10.1016/j.vaccine.2012.10.099.PubMedCrossRefGoogle Scholar
  178. Porta M, Gonzalez B, Marquez S, Artazcoz L. Doubts on the appropriateness of universal human papillomavirus vaccination: is evidence on public health benefits already available? J Epidemiol Community Health. 2008;62:667. doi: 10.1136/jech.2007.073528.PubMedCrossRefGoogle Scholar
  179. Prue G. Human papillomavirus: a strong case for vaccinating boys. Trends in Urology & Men's Health. 2016;7:7–11. doi: 10.1002/tre.499.CrossRefGoogle Scholar
  180. Rahman M, Laz TH, McGrath CJ, Berenson AB. Provider recommendation mediates the relationship between parental human papillomavirus (HPV) vaccine awareness and HPV vaccine initiation and completion among 13- to 17-year-old U.S. adolescent children. Clin Pediatr (Phila). 2015;54:371–5. doi: 10.1177/0009922814551135.CrossRefGoogle Scholar
  181. Rail G, Lippman A. Appel urgent à un moratoire sur la vaccination contre les VPH. Montréal, QC: Le Devoir; 2015.Google Scholar
  182. Rank C, Gilbert M, Ogilvie G, Jayaraman GC, Marchand R, Trussler T, Hogg RS, Gustafson R, Wong T. Acceptability of human papillomavirus vaccination and sexual experience prior to disclosure to health care providers among men who have sex with men in Vancouver, Canada: implications for targeted vaccination programs. Vaccine. 2012;30:5755–60. doi: 10.1016/j.vaccine.2012.07.001.PubMedCrossRefGoogle Scholar
  183. Reisinger KS, Block SL, Lazcano-Ponce E, Samakoses R, Esser MT, Erick J, Puchalski D, Giacoletti KE, Sings HL, Lukac S. Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial. Pediatr Infect Dis J. 2007;26:201–9.PubMedCrossRefGoogle Scholar
  184. Reist MT, Klein R. Why are we experimenting with drugs on girls? The Age. http://www.theage.com.au/news/opinion/why-are-we-experimenting-with-drugs-on-girls/2007/05/24/1179601570922.html. 2007. Accessed 5 Apr 2016.
  185. Rothman SM, Rothman DJ. Marketing hpv vaccine: implications for adolescent health and medical professionalism. JAMA. 2009;302:781–6. doi: 10.1001/jama.2009.1179.PubMedCrossRefGoogle Scholar
  186. de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, Tous S, Felix A, Bravo LE, Shin HR, Vallejos CS, de Ruiz PA, Lima MA, Guimera N, Clavero O, Alejo M, Llombart-Bosch A, Cheng-Yang C, Tatti SA, Kasamatsu E, Iljazovic E, Odida M, Prado R, Seoud M, Grce M, Usubutun A, Jain A, Suarez GA, Lombardi LE, Banjo A, Menendez C, Domingo EJ, Velasco J, Nessa A, Chichareon SC, Qiao YL, Lerma E, Garland SM, Sasagawa T, Ferrera A, Hammouda D, Mariani L, Pelayo A, Steiner I, Oliva E, Meijer CJ, Al-Jassar WF, Cruz E, Wright TC, Puras A, Llave CL, Tzardi M, Agorastos T, Garcia-Barriola V, Clavel C, Ordi J, Andujar M, Castellsague X, Sanchez GI, Nowakowski AM, Bornstein J, Munoz N, Bosch FX, Retrospective International S, Group HPVTTS. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010;11:1048–56. doi: 10.1016/S1470-2045(10)70230-8.PubMedCrossRefGoogle Scholar
  187. Sasieni P, Castanon A, Cuzick J. Effectiveness of cervical screening with age: population based case-control study of prospectively recorded data. BMJ. 2009;339:b2968.PubMedPubMedCentralCrossRefGoogle Scholar
  188. Scheller N, Pasternak B, Svanström H, Hviid A. Quadrivalent human papillomavirus vaccine and the risk of venous thromboembolism. JAMA. 2014;312:187–8. doi: 10.1001/jama.2014.2198.PubMedCrossRefGoogle Scholar
  189. Scheller NM, Svanstrom H, Pasternak B, Arnheim-Dahlstrom L, Sundstrom K, Fink K, Hviid A. Quadrivalent HPV vaccination and risk of multiple sclerosis and other demyelinating diseases of the central nervous system. JAMA. 2015;313:54–61. doi: 10.1001/jama.2014.16946.PubMedCrossRefGoogle Scholar
  190. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet. 2007;370:890–907. doi: 10.1016/S0140-6736(07)61416-0.PubMedCrossRefGoogle Scholar
  191. Schiller JT, Castellsagué X, Garland SM. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine. 2012;30:F123–38. doi: 10.1016/j.vaccine.2012.04.108.PubMedPubMedCentralCrossRefGoogle Scholar
  192. Schmidt H. Public health ethics. In: Chadwick R, editor. Encyclopedia of applied ethics. 2nd ed. San Diego, CA: Academic; 2012. p. 685–95.CrossRefGoogle Scholar
  193. Schwarz TF, Huang LM, Lin TY, Wittermann C, Panzer F, Valencia A, Suryakiran PV, Lin L, Descamps D. Long-term immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in 10- to 14-year-old girls: open 6-year follow-up of an initial observer-blinded, randomized trial. Pediatr Infect Dis J. 2014;33:1255–61. doi: 10.1097/inf.0000000000000460.PubMedCrossRefGoogle Scholar
  194. Serpell L, Green J. Parental decision-making in childhood vaccination. Vaccine. 2006;24:4041–6. doi: 10.1016/j.vaccine.2006.02.037.PubMedCrossRefGoogle Scholar
  195. Seto K, Marra F, Raymakers A, Marra CA. The cost effectiveness of human papillomavirus vaccines: a systematic review. Drugs. 2012;72:715–43. doi: 10.2165/11599470-000000000-00000.PubMedCrossRefGoogle Scholar
  196. Shah KV. A case for immunization of human papillomavirus (HPV) 6/11-infected pregnant women with the quadrivalent HPV vaccine to prevent juvenile-onset laryngeal papilloma. J Infect Dis. 2014;209:1307–9. doi: 10.1093/infdis/jit611.PubMedCrossRefGoogle Scholar
  197. Sharp L, Cotton S, Cochran C, Gray N, Little J, Neal K, Cruickshank M. After-effects reported by women following colposcopy, cervical biopsies and LLETZ: results from the TOMBOLA trial. BJOG. 2009;116:1506–14. doi: 10.1111/j.1471-0528.2009.02263.x.PubMedCrossRefGoogle Scholar
  198. Sigurdsson K. The Icelandic and Nordic cervical screening programs: trends in incidence and mortality rates through 1995. Acta Obstet Gynecol Scand. 1999;78:478–85.PubMedCrossRefGoogle Scholar
  199. Singh GK, Miller BA, Hankey BF, Edwards BK. Persistent area socioeconomic disparities in U.S. incidence of cervical cancer, mortality, stage, and survival, 1975–2000. Cancer. 2004;101:1051–7. doi: 10.1002/cncr.20467.PubMedCrossRefGoogle Scholar
  200. Sinka K, Kavanagh K, Gordon R, Love J, Potts A, Donaghy M, Robertson C. Achieving high and equitable coverage of adolescent HPV vaccine in Scotland. J Epidemiol Community Health. 2014;68:57–63. doi: 10.1136/jech-2013-202620.PubMedCrossRefGoogle Scholar
  201. Slade BA, Leidel L, Vellozzi C, et al. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. JAMA. 2009;302:750–7. doi: 10.1001/jama.2009.1201.PubMedCrossRefGoogle Scholar
  202. Smith MJ, Ellenberg SS, Bell LM, Rubin DM. Media coverage of the measles-mumps-rubella vaccine and autism controversy and its relationship to MMR immunization rates in the United States. Pediatrics. 2008;121:e836–43. doi: 10.1542/peds.2007-1760.PubMedCrossRefGoogle Scholar
  203. Smith RW, Henry F, Pettipas G, Motiuk D, Chatlain M, Bouchard L. A Message from the Alberta Catholic Bishops to Parents, Trustees, Superintendents of Education of Catholic School Boards and to the Catholic Educational Community. In: The Catholic Archdiocese of Edmonton. http://www.caedm.ca/Archbishop/PastoralLetters/MessageonHPVVaccinationProgramJune2008.aspx. 2008. Accessed 17 Feb 2016.
  204. Smith LM, Kaufman JS, Strumpf EC, Lévesque LE. Effect of human papillomavirus (HPV) vaccination on clinical indicators of sexual behaviour among adolescent girls: the Ontario grade 8 HPV vaccine cohort study. Can Med Assoc J. 2015;187:E74–81. doi: 10.1503/cmaj.140900.CrossRefGoogle Scholar
  205. Smith HO, Tiffany MF, Qualls CR, Key CR. The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States—a 24-year population-based study. Gynecol Oncol. 2000;78:97–105. doi: 10.1006/gyno.2000.5826.PubMedCrossRefGoogle Scholar
  206. Spinosa JP, Riva C, Biollaz J. Letter to the editor response to the article of Luisa Lina villa HPV prophylactic vaccination: the first years and what to expect from now, in press. Cancer Lett. 2011;304:70. doi: 10.1016/j.canlet.2011.01.024.PubMedCrossRefGoogle Scholar
  207. Stokley S, Jeyarajah J, Yankey D, Cano M, Gee J, Roark J, Curtis RC, Markowitz L. Human papillomavirus vaccination coverage among adolescents, 2007-2013, and postlicensure vaccine safety monitoring, 2006-2014–United States. MMWR Morb Mortal Wkly Rep. 2014;63:620–4.PubMedGoogle Scholar
  208. Suba EJ, Gonzalez-Mena LE, Van Thai NE, Raab SS. RE: population-level impact of the bivalent, quadrivalent, and candidate nonavalent human papillomavirus vaccines: a comparative model-based analysis. J Natl Cancer Inst. 2013;105:664.; discussion 665–6. doi: 10.1093/jnci/djt060.PubMedCrossRefGoogle Scholar
  209. Syrjänen KJ. Prophylactic HPV vaccines: the Finnish perspective. Expert Rev Vaccines. 2010;9:45–57. doi: 10.1586/erv.09.140.PubMedCrossRefGoogle Scholar
  210. Syrjanen S, Waterboer T, Sarkola M, Michael K, Rintala M, Syrjanen K, Grenman S, Pawlita M. Dynamics of human papillomavirus serology in women followed up for 36 months after pregnancy. J Gen Virol. 2009;90:1515–26. doi: 10.1099/vir.0.007823-0.PubMedCrossRefGoogle Scholar
  211. The Lancet. GAVI injects new life into HPV vaccine rollout. Lancet. 2013;381:1688. doi: 10.1016/S0140-6736(13)61058-2.Google Scholar
  212. Thomas KK, Hughes JP, Kuypers JM, Kiviat NB, Lee SK, Adam DE, Koutsky LA. Concurrent and sequential acquisition of different genital human papillomavirus types. J Infect Dis. 2000;182:1097–102. doi: 10.1086/315805.PubMedCrossRefGoogle Scholar
  213. Thompson A. Human papilloma virus, vaccination and social justice: an analysis of a Canadian school-based vaccine program. Public Health Ethics. 2013;6:11–20. doi: 10.1093/phe/pht010.CrossRefGoogle Scholar
  214. Thompson A, Polzer J. School based HPV vaccination for girls in Ontario. In: Population and public health ethics. Canadian Institutes of Health Research - Institute of Population and Public Health ed. Toronto, ON: Cases from Research, Policy, and Practice; 2012. p. 103–13.Google Scholar
  215. Tjalma WA, van Damme P. Who should be vaccinated against human papillomavirus? Int J Gynecol Cancer. 2006;16:1498–9. doi: 10.1111/j.1525-1438.2006.00620.x.PubMedCrossRefGoogle Scholar
  216. Tomljenovic L, Shaw C. Death after quadrivalent human papillomavirus (HPV) vaccination: causal or coincidental. Pharmaceut Reg Affairs S. 2012a;12:2–001.Google Scholar
  217. Tomljenovic L, Shaw CA. Too fast or not too fast: the FDA's approval of Merck's HPV vaccine Gardasil. J Law Med Ethics. 2012b;40:673–81. doi: 10.1111/j.1748-720X.2012.00698.x.PubMedCrossRefGoogle Scholar
  218. Tomljenovic L, Shaw CA. Human papillomavirus (HPV) vaccine policy and evidence-based medicine: are they at odds? Ann Med. 2013;45:182–93. doi: 10.3109/07853890.2011.645353.PubMedCrossRefGoogle Scholar
  219. Tomljenovic L, Wilyman J, Vanamee E, Bark T, Shaw CA. HPV vaccines and cancer prevention, science versus activism. Infectious Agents and Cancer. 2013;8:6–6. doi: 10.1186/1750-9378-8-6.PubMedPubMedCentralCrossRefGoogle Scholar
  220. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108. doi: 10.3322/caac.21262.PubMedCrossRefGoogle Scholar
  221. Tota JE, Ramanakumar AV, Jiang M, Dillner J, Walter SD, Kaufman JS, Coutlee F, Villa LL, Franco EL. Epidemiologic approaches to evaluating the potential for human papillomavirus type replacement postvaccination. Am J Epidemiol. 2013;178:625–34. doi: 10.1093/aje/kwt018.PubMedPubMedCentralCrossRefGoogle Scholar
  222. Trinquart L, Johns DM, Galea S. Why do we think we know what we know? A metaknowledge analysis of the salt controversy. Int J Epidemiol. 2016;45:251–60. doi: 10.1093/ije/dyv184.PubMedCrossRefGoogle Scholar
  223. Tsu VD, Levin CE. Making the case for cervical cancer prevention: what about equity? Reprod Health Matters. 2008;16:104–12. doi: 10.1016/s0968-8080(08)32411-2.PubMedCrossRefGoogle Scholar
  224. Vaccarella S, Clifford GM, Howell-Jones R, Snijders PJ, Franceschi S, International Agency for Research on Cancer Multicentric Cervical Cancer Study Group. Author's reply to: multiple human papillomavirus genotype infections in cervical cancer progression in the study to understand cervical cancer early endpoints and determinants. Int J Cancer. 2011;129:1283–5. doi: 10.1002/ijc.25774.PubMedCrossRefGoogle Scholar
  225. Vaccarella S, Lortet-Tieulent J, Plummer M, Franceschi S, Bray F. Worldwide trends in cervical cancer incidence: impact of screening against changes in disease risk factors. Eur J Cancer. 2013;49:3262–73. doi: 10.1016/j.ejca.2013.04.024.PubMedCrossRefGoogle Scholar
  226. Vaccarella S, Plummer M, Franceschi S, Gravitt P, Papenfuss M, Smith D, Villa L, Ponce EL, Giuliano AR. Clustering of human papillomavirus (HPV) types in the male genital tract: the HPV in men (HIM) study. J Infect Dis. 2011;204:1500–4. doi: 10.1093/infdis/jir595.PubMedPubMedCentralCrossRefGoogle Scholar
  227. Vaccarella S, Soderlund-Strand A, Franceschi S, Plummer M, Dillner J. Patterns of human papillomavirus types in multiple infections: an analysis in women and men of the high throughput human papillomavirus monitoring study. PLoS One. 2013;8:e71617. doi: 10.1371/journal.pone.0071617.PubMedPubMedCentralCrossRefGoogle Scholar
  228. Van Doorslaer K. Evolution of the papillomaviridae. Virology. 2013;445:11–20. doi: 10.1016/j.virol.2013.05.012.PubMedCrossRefGoogle Scholar
  229. Vesikari T, Brodszki N, van Damme P, Diez-Domingo J, Icardi G, Petersen LK, Tran C, Thomas S, Luxembourg A, Baudin M. A randomized, double-blind, phase III study of the immunogenicity and safety of a 9-valent human papillomavirus L1 virus-like particle vaccine (V503) versus Gardasil(R) in 9-15-year-old girls. Pediatr Infect Dis J. 2015;34:992–8. doi: 10.1097/inf.0000000000000773.PubMedCrossRefGoogle Scholar
  230. Vichnin M, Bonanni P, Klein NP, Garland SM, Block SL, Kjaer SK, Sings HL, Perez G, Haupt RM, Saah AJ, Lievano F, Velicer C, Drury R, Kuter BJ. An overview of Quadrivalent human papillomavirus vaccine safety: 2006 to 2015. Pediatr Infect Dis J. 2015;34:983–91. doi: 10.1097/inf.0000000000000793.PubMedCrossRefGoogle Scholar
  231. Villa LL, Ault KA, Giuliano AR, Costa RL, Petta CA, Andrade RP, Brown DR, Ferenczy A, Harper DM, Koutsky LA, Kurman RJ, Lehtinen M, Malm C, Olsson SE, Ronnett BM, Skjeldestad FE, Steinwall M, Stoler MH, Wheeler CM, Taddeo FJ, Yu J, Lupinacci L, Railkar R, Marchese R, Esser MT, Bryan J, Jansen KU, Sings HL, Tamms GM, Saah AJ, Barr E. Immunologic responses following administration of a vaccine targeting human papillomavirus types 6, 11, 16, and 18. Vaccine. 2006;24:5571–83. doi: 10.1016/j.vaccine.2006.04.068.PubMedCrossRefGoogle Scholar
  232. Vizcaino AP, Moreno V, Bosch FX, Munoz N, Barros-Dios XM, Borras J, Parkin DM. International trends in incidence of cervical cancer: II. Squamous-cell carcinoma. Int J Cancer. 2000;86:429–35.PubMedCrossRefGoogle Scholar
  233. de Vries E, Arroyave I, Pardo C, Wiesner C, Murillo R, Forman D, Burdorf A, Avendaño M. Trends in inequalities in premature cancer mortality by educational level in Colombia, 1998–2007. J Epidemiol Community Health. 2015;69:408–15. doi: 10.1136/jech-2014-204650.PubMedCrossRefGoogle Scholar
  234. Wakefield AJ, Murch SH, Anthony A, Linnell J, Casson DM, Malik M, Berelowitz M, Dhillon AP, Thomson MA, Harvey P, Valentine A, Davies SE, Walker-Smith JA. RETRACTED: Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet. 1998;351:637–41. doi: 10.1016/S0140-6736(97)11096-0.PubMedCrossRefGoogle Scholar
  235. Waller J, Marlow LAV, Wardle J. Mothers' attitudes towards preventing cervical cancer through human papillomavirus vaccination: a qualitative study. Cancer Epidemiol Biomark Prev. 2006;15:1257–61. doi: 10.1158/1055-9965.epi-06-0041.CrossRefGoogle Scholar
  236. Watson M, Shaw D, Molchanoff L, McInnes C. Challenges, lessons learned and results following the implementation of a human papilloma virus school vaccination program in South Australia. Aust N Z J Public Health. 2009;33:365–70. doi: 10.1111/j.1753-6405.2009.00409.x.PubMedCrossRefGoogle Scholar
  237. Weinberger DM, Malley R, Lipsitch M. Serotype replacement in disease after pneumococcal vaccination. Lancet. 2011;378:1962–73. doi: 10.1016/S0140-6736(10)62225-8.PubMedPubMedCentralCrossRefGoogle Scholar
  238. Wheeler CM, Castellsague X, Garland SM, Szarewski A, Paavonen J, Naud P, Salmeron J, Chow SN, Apter D, Kitchener H, Teixeira JC, Skinner SR, Jaisamrarn U, Limson G, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, Bosch FX, Harper DM, Huh W, Hardt K, Zahaf T, Descamps D, Struyf F, Dubin G, Lehtinen M, Group HPS. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 2012;13:100–10. doi: 10.1016/S1470-2045(11)70287-X.PubMedCrossRefGoogle Scholar
  239. Wilson SE, Karas E, Crowcroft NS, Bontovics E, Deeks SL. Ontario's school-based HPV immunization program: school board assent and parental consent. Can J Public Health. 2012;103:34–9.PubMedGoogle Scholar
  240. Wingle J. Ontario bishops message on HPV innoculation in Catholic schools. https://ccrl.ca/2007/09/ontario-bishops-message-on-hpv-innoculation-in-catholic-schools/. 2007. Accessed 18 Feb 2016.
  241. Wolfe RM, Sharp LK. Anti-vaccinationists past and present. BMJ. 2002;325:430–2. doi: 10.1136/bmj.325.7361.430.PubMedPubMedCentralCrossRefGoogle Scholar
  242. Zimmerman RK. Ethical analysis of HPV vaccine policy options. Vaccine. 2006;24:4812–20. doi: 10.1016/j.vaccine.2006.03.019.PubMedCrossRefGoogle Scholar
  243. Zou H, Grulich AE, Cornall AM, Tabrizi SN, Garland SM, Prestage G, Bradshaw CS, Hocking JS, Morrow A, Fairley CK, Chen MY. How very young men who have sex with men view vaccination against human papillomavirus. Vaccine. 2014;32:3936–41. doi: 10.1016/j.vaccine.2014.05.043.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG 2018

Authors and Affiliations

  1. 1.Division of Cancer EpidemiologyMcGill UniversityMontrealCanada

Personalised recommendations